Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 1 | -$4.40 | -$4.40 | -$4.40 |
Q2 2025 | 1 | -$4.64 | -$4.64 | -$4.64 |
Q3 2025 | 1 | -$4.80 | -$4.80 | -$4.80 |
Q4 2025 | 1 | -$5.04 | -$5.04 | -$5.04 |
ASLAN Pharmaceuticals Limited last posted its earnings results on Friday, August 9th, 2024. The company reported $-0.88 earnings per share for the quarter, topping analysts' consensus estimates of $-3.6 by $2.72. The company had revenue of 0 for the quarter and had revenue of 12.00 M for the year. ASLAN Pharmaceuticals Limited has generated $-3 earnings per share over the last year ($-2.69 diluted earnings per share) and currently has a price-to-earnings ratio of -0.32. ASLAN Pharmaceuticals Limited has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
03/30/2024 | Q1 2024 | -$0.53 | $0 | $0 | ||
04/12/2024 | Q4 2023 | -$0.61 | -$0.78 | -0.17 | $0 | |
08/18/2023 | Q3 2023 | -$0.56 | $0 | |||
08/18/2023 | Q2 2023 | -$0.11 | $12.00 M | |||
03/31/2023 | Q1 2023 | -$1.29 | $0 | |||
03/24/2023 | Q4 2022 | -$7.60 | -$1.04 | 6.56 | $0 | |
09/29/2022 | Q3 2022 | -$0.78 | $0 | |||
06/29/2022 | Q2 2022 | -$0.92 | $0 | |||
03/31/2022 | Q1 2022 | -$0.92 | $0 | |||
03/25/2022 | Q4 2021 | -$6.00 | -$0.66 | 5.34 | $0 | |
09/29/2021 | Q3 2021 | -$0.61 | $0 | |||
08/06/2021 | Q2 2021 | -$4.40 | -$0.39 | 4.01 | $0 | |
01/29/2021 | Q1 2021 | -$0.65 | $0 | |||
04/23/2021 | Q4 2020 | -$0.72 | $0 | |||
09/29/2020 | Q3 2020 | -$0.43 | $0 | |||
10/09/2020 | Q2 2020 | -$0.52 | $0 | |||
03/31/2020 | Q1 2020 | -$0.40 | $0 | |||
04/16/2020 | Q4 2019 | -$4.39 | $0 | |||
10/31/2019 | Q3 2019 | -$8.80 | -$0.81 | 7.99 | $0 | |
10/31/2019 | Q2 2019 | -$8.80 | -$1.24 | 7.56 | $0 |
ASLAN Pharmaceuticals Limited has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates.
In the previous quarter, ASLAN Pharmaceuticals Limited (:ASLN) reported $-0.88 earnings per share (EPS) to beat the analysts' consensus estimate of $-3.6 by $2.72.
The conference call for ASLAN Pharmaceuticals Limited's latest earnings report can be listened to online.
The conference call transcript for ASLAN Pharmaceuticals Limited's latest earnings report can be read online.
ASLAN Pharmaceuticals Limited (:ASLN) has a recorded annual revenue of $12.00 M.
ASLAN Pharmaceuticals Limited (:ASLN) has a recorded net income of $12.00 M. ASLAN Pharmaceuticals Limited has generated $-2.69 earnings per share over the last four quarters.
ASLAN Pharmaceuticals Limited (:ASLN) has a price-to-earnings ratio of -0.32 and price/earnings-to-growth ratio is -0.01.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED